See the difference

Increased flexibility lowers the potential for stent fracture:¹

• Open-cell structure: The continuous spine-free stent is designed to promote optimal blood flow and eliminate high-strain stress zones that can lead to fracture¹
• In the JP-OSPREY clinical trial, 0% incidence of stent fracture per stent at 12 months post-procedure³
• Optimized radial force to reduce thrombosis and neointima hyperplasia²

Feel the difference

​Responds to a patient’s natural anatomy with increased conformability⁶:

• Responsive in-vitro performance even in severe bend situations.¹ In comparison to other self-expanding nitinol stents tested, Misago demonstrated high flexibility and durability in rigorous fatigue-testing simulations.
• No stent fractures recorded during:
• 40% compression test that simulated the response during thigh contraction
• 90° torsion test that simulated the rotation between supine and fetal position
• More flexible stents may be associated with improved patency⁷
• Precision deployment with 100% delivery success³
• Minimizes jumping, recoil or foreshortening with an easy-to-use thumbwheel system that allows for single operator deployment
• Enables exact stent placement with the pushability of a triaxial catheter design

Make a difference

​Realize meaningful long-term outcomes in superficial femoral and popliteal arteries.⁸

Clinically proven results in difficult to treat lesions:

• In long calcified lesions (> 8 cm)⁹
  90.3% Primary patency rate at 1 year
• In popliteal lesions (p1-p3)¹⁰
  91.5% Primary patency rate at 1 year